References:
- Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic
aspects. Circ Res 2016; 118:1340–1347.
- Konstantinides SV, Meyer G, Becattini
C, et al . Management of
acute pulmonary embolism of the European Society of, C. (2019). 2019
ESC Guidelines for the diagnosis and management of acute pulmonary
embolism developed in collaboration with the European Respiratory
Society (ERS): The Task Force for the diagnosis and management of
acute pulmonary embolism of the European Society of Cardiology (ESC).Eur Respir J. 2019; Oct 9;54(3):1901647. doi:
10.1183/13993003.01647-2019.
- Dickson BC. Venous thrombosis: on the history of Virchow’s triad. Univ
Toronto Med J 2004; 81:166.
- Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br
J Haematol 2008; 143:180.
- Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous
thromboembolism risk: a meta-analysis. Pharmacopsychiatry
2011;44:183–8.
- Chapelle C, Quenet S, Delavenne X, Lacut K, Mismetti P, Laporte S, et
al.Antipsychotics: a real or confounding risk factor for venous
thromboembolism Pharmacopsychiatry 2013;46:36–7
- Hägg S, Spigset O. Antipsychotic-induced venous tromboembolism: a
review of the evidence. CNS Drugs 2002;16:765-76.
- Duggirala, H. J. et al. Use of data mining at the Food and Drug
Administration. J. Am. Med. Inform. Assoc. 23, 428–434 (2016).
- Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting
ratios (PRRs) for signal generation from spontaneous adverse drug
reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483–486 (2001)
- McGrath J, Saha S, Chant D. Schizophrenia: a concise overview of
incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67.
- FDA. FDA adverse event reporting system (FAERS) quarterly data extract
files. 2021; https:// fis. fda. gov/ exten sions/ FPD- QDEFAERS/FPD-
QDE- FAERS. html. Accessed 29 Jan 2021.
- Chunyan Wei , Ying Liu, Aidou Jiang, et al.A pharmacovigilance study
of the association between tetracyclines and hepatotoxicity based on
Food and Drug Administration adverse event reporting system dataInt J
Clin Pharm.2022.44:709–716
- Xu H, Stenner SP, Doan S, et al. MedEx: a medication information
extraction system for clinical narratives. J Am Med Inform
Assoc.2010;17(1):19–24.
- Bin Wu, Dan Li, Ting Xu, et al.Proton pump inhibitors associated acute
kidney injury and chronic kidney disease: data mining of US FDA
adverse event reportingsystem.Sci Rep. 2021 Feb 11;11(1):3690. doi:
10.1038/s41598-021-83099-y.
- Jönsson AK, Brudin L, Ahlner J, Hedenmalm K, Ericsson A, Hägg S.
Antipsychotics associated with pulmonary embolism in a Swedish
medicolegal autopsy series.Int Clin Psychopharmacol 2008;23:263-8.
- Jönsson AK, Horváth-Puhó E, Hägg S, Pedersen L, Sorensen HT.
Antipsychotics andrisk of venous thromboembolism: A population based
case–control study. Clin Epidemiol 2009;1:19-26.
- Lacut K, Le Gal G, Couturaud F, Cornily G, Leroyer C, Mottier D, et
al. Association between antipsychotic drugs, antidepressant drugs and
venous thrmoboembolism:results from the EDITH case–control study.
Fundam Clin Pharmacol 2007;21:643-50.
- Waage IM, Gedde-DahlA.Pulmonary embolism possiblyassociated with
olanzapinetreatment. BMJ 2003;327:384.
- Kamijo Y, Soma K, Nagai T, Kurihara K, Ohwada T. Acute massive
pulmonary thromboembolism associated with risperidone and convetional
phenothiazines.Circ J 2003;67:46-8.
- Borras L, Eytan A, de Timary P, Constant EL, Huguelet P, Hermans C.
Pulmonary thromboembolism associated with olanzapine and risperidone.
J Emerg Med 2007;35:159-61.
- Malý R, Masopust J, Hosák L, Urban A. Four cases of venous
thromboembolism associated with olanzapine. Psychiatry Clin Neurosci
2009;63:116-8.
- Hägg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism.
Int Clin Psychopharmacol 2003;18:299-300.
- Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J. Homocysteine
levels in newly admitted schizophrenic patients. J Psychiatr Res
2004;38:413-6.
- Walsh MT, Ryan M, Hillmann A, Condren R, Kenny D, Dinan T, et al.
Elevated expression of integrin alpha(IIb) beta(IIIa) in drug-naïve,
first episode schizophrenic patients. Biol Psychiatry 2002;52:874-9.
- Masopust J, Malý R, Andrýs C, Vališ M, Bažant J, Hosák L. Markers of
thrombogenesisare activated in unmedicated patients with acute
psychosis: a matched case controlstudy. BMC Psychiatry 2011;11:2.
- Kunutsor SK, Seidu S and Khunti K. Depression, antidepressant use, and
risk of venous thromboembolism: systematic review and meta-analysis of
published observational evidence. Ann Med 2018; 50: 529-537.
2018/07/14. DOI: 10.1080/07853890.2018.1500703.
- Letmaier M, Grohmann R, Kren C, et al. Venous thromboembolism during
treatment with antipsychotics: Results of a drug surveillance
programme. World J Biol Psychiatry 2018; 19: 175-186.DOI:
10.1080/15622975.2017.1285048.
- Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global Epidemiology and
Burden of Schizophrenia: Findings From the Global Burden of Disease
Study 2016. Schizophr Bull 2018;44: 1195-1203. DOI:
10.1093/schbul/sby058.
- Cécile Tromeur, Francis Couturaud. ntipsychotic drugs and venous
thromboembolism.Thrombosis Research 130 (2012) S29–S31.